… After binding to the PSMA receptor, [ 177 Lu]Lu-PSMA-617 is internalized into the PSMA …
The suitability of [ 177 Lu]Lu-PSMA-617 for the treatment of prostate cancer patients was …

… treatment with [ 177 Lu]-PSMA-617 has high response rates, low toxic effects, and reduction
of pain in men with metastatic castration-resistant prostate cancer who have progressed …

… efficacy of 177 Lu prostate specific membrane antigen (PSMA) radioligand therapy (… prostate
cancer (mCRPC). The aim of our systematic review was to elucidate whether 177 Lu-PSMA …

… prostate-specific membrane antigen (PSMA) have been established for the treatment of
metastasized castration-resistant prostate cancer (… patients treated with 177 Lu-PSMA-617. …

… castration-resistant prostate cancer (mCRPC) 1 . However, the treatment of mCRPC
patients with 177 Lu-PSMA-617 (Lu-PSMA) achieves biochemical response (> 50% decline of …

… end-stage prostate cancer receiving Lu-PSMA therapy [12, 15]. In line with the concept of
theranostics, high SUV mean is associated with higher tumor doses of Lu-PSMA therapy and …

… Prostate-specific membrane antigen (PSMA) is overexpressed in metastatic castration-resistant
prostate cancer (… trial of 177 Lu-PSMA-617 radioligand therapy in men with high PSMA …

… Lu-PSMA RLT targets PSMA, which is expressed at high levels on the surface of prostate
cancer cells (4). PSMA expression remains high in metastases even after multiple lines of …

… , and safety associated with 177 Lu-PSMA-617 RLT in a … control by 177 Lu-PSMA-617 RLT,
as reflected by prostate-specific … biochemical disease control by 177 Lu-PSMA-617 RLT was …

… with metastatic castration-resistant prostate cancer. We aimed to compare [ 177 Lu]Lu-PSMA-617
with cabazitaxel in patients with metastatic castration-resistant prostate cancer. …